US8684591089 - SUPN - A1JX3U (XNMS)
SUPERNUS PHARMACEUTICALS INC Aktie
32,13 USD
Aktuelle Kurse von SUPERNUS PHARMACEUTICALS INC
Börse | Ticker | Währung | Letzter Umsatz | Kurs | Tagesveränderung | Tagesveränderung % |
---|---|---|---|---|---|---|
NASDAQ |
SUPN
|
USD
|
19.09.2024 22:00
|
32,13 USD
| 31,84 USD | 0,91 % |
London |
0LB2.L
|
USD
|
19.09.2024 17:39
|
31,97 USD
| 31,84 USD | 0,41 % |
Performance
Tag | Woche | Monat | 3 Monate | 6 Monate | 1 Jahr | 5 Jahre |
---|---|---|---|---|---|---|
0,00 % | 3,28 % | -6,45 % | 20,52 % | -6,84 % | 12,97 % | 10,87 % |
Firmenprofil zu SUPERNUS PHARMACEUTICALS INC Aktie
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.
Investierte Fonds
Folgende Fonds haben in SUPERNUS PHARMACEUTICALS INC investiert:
Fonds | Vol. in Mio 49,89 | Anteil (%) 0,12 % |
Unternehmensdaten zur SUPERNUS PHARMACEUTICALS INC Aktie
Name SUPERNUS PHARMACEUTICALS INC
Firma Supernus Pharmaceuticals, Inc.
Symbol SUPN
Website https://www.supernus.com
Heimatbörse
NASDAQ/NMS (GLOBAL MARKET)
WKN A1JX3U
ISIN US8684591089
Wertpapierart Aktie
Sektor Healthcare
Branche Drug Manufacturers - Specialty & Generic
CEO Mr. Jack A. Khattar M.B.A.
Marktkapitalisierung 2 Mrd.
Land Vereinigte Staaten von Amerika
Währung USD
Mitarbeiter 0,7 T
Adresse 9715 Key West Avenue, 20850 Rockville
IPO Datum 2012-05-01
Ticker Symbole
Name | Symbol |
---|---|
Frankfurt | S49.F |
London | 0LB2.L |
NASDAQ | SUPN |
Weitere Aktien
Investoren die SUPERNUS PHARMACEUTICALS INC halten haben auch folgende Aktien im Depot:
Die Finanzplattform goSPATZ trackt und analysiert Investitionen und Portfolios.
Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
All rights reserved © LCP GmbH 2024